Gilead Sciences, Inc. (GILD)
Nasdaq: GILD · Biological Products, (No Diagnostic Substances) · Foster City, CA · filing with the SEC since 1994
Grade6.8
◀ Past 7.3● Present 7.5▶ Future 5.3
Who owns Gilead Sciences, Inc.
As filed with the SECHolders of 5% or more
3
Blackrock, Inc. holds 8.2% of Common Stock, as its SCHEDULE 13G/A filed Apr 24, 2025 says.
Directors and officers
16
report now, of 38 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 24, 2025 · Common Stock
Vanguard Capital Management
SCHEDULE 13G · filed Apr 29, 2026 · Common Stock
Fmr LLC
SCHEDULE 13G · filed Feb 5, 2026 · COMMON STOCK
Capital World Investors
SCHEDULE 13G/A · filed May 13, 2025 · Common Stock · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
What GILD reports owning in othersstakes of 5% or more, and other ties
Arcellx, Inc.
SCHEDULE 13D/A · filed Apr 28, 2026 · Common Stock, par value $0.001
Lakefront Biotherapeutics LKFT
SCHEDULE 13D/A · filed Jan 10, 2025 · Ordinary Shares, no par value
Assembly Biosciences, Inc. ASMB
SCHEDULE 13D/A · filed May 27, 2026 · Common Stock, par value $0.001
Arcus Biosciences, Inc. RCUS
SCHEDULE 13D/A · filed Aug 7, 2026 · Common Stock, par value $0.0001
Xilio Therapeutics, Inc. XLO
SCHEDULE 13G/A · filed Feb 12, 2026 · Common Stock, par value $0.0001 per share
Kalaris Therapeutics, Inc. KLRS
SCHEDULE 13G/A · filed Mar 20, 2025 · Common Stock, $0.0001 per value · reported falling below 5%
ImageneBio, Inc. IMA
SCHEDULE 13G/A · filed Feb 13, 2025 · Common Stock · reported falling below 5%
Cypherpunk Technologies Inc. CYPH
SCHEDULE 13G/A · filed Feb 12, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%
Other ties the annual report names
Arcellx, Inc
An investee · investee · invested in, named in the 10-K filed Feb 24, 2026
Arcus Biosciences, Inc.
An investee · investee · invested in, named in the 10-K filed Feb 24, 2026
Cyma Bay
A company bought · asset acquisition · owns, named in the 10-K filed Feb 24, 2026
Interius BioTherapeutics
A company bought · asset acquisition · owns, named in the 10-K filed Feb 24, 2026
Tmunity Therapeutics
A company bought · asset acquisition · owns, named in the 10-K filed Feb 24, 2026
XinThera, Inc
A company bought · asset acquisition · owns, named in the 10-K filed Feb 24, 2026
84 subsidiaries in 42 countries, from the list filed with the 10-K filed Feb 24, 2026. Its Form 13F-HR for Jun 30, 2026 lists 5 holdings. The record carries no value for them.
Insider tradesForm 4
86sales
0purchases
85sales on a scheduled plan
8people selling
$112Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 9, 2025 to Nov 9, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 9, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window8 of 39 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| O'Day Daniel Patrick | Chairman & CEO | 34 | $76.3M | 34 | 0 | $0 |
| Mercier Johanna | Chief Comm & Corp Aff Officer | 23 | $18.6M | 23 | 0 | $0 |
| Telman Deborah H | EVP, Corporate Affairs & GC | 3 | $6.6M | 3 | 0 | $0 |
| Dickinson Andrew D | Chief Financial Officer | 12 | $4.9M | 12 | 0 | $0 |
| Welters Anthony | director | 4 | $2.7M | 4 | 0 | $0 |
| Bluestone Jeffrey | director | 7 | $2.0M | 6 | 0 | $0 |
| Kramer Kelly A. | director | 2 | $700,000 | 2 | 0 | $0 |
| Cain Wettan Keeley M | EVP Gen Counsel, Legal & Comp | 1 | $600,000 | 1 | 0 | $0 |